

Riccardo Ponzzone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6617142/publications.pdf>

Version: 2024-02-01

102
papers

3,573
citations

109321

35
h-index

144013

57
g-index

104
all docs

104
docs citations

104
times ranked

4340
citing authors

#	ARTICLE	IF	CITATIONS
1	Menopause after breast cancer: a survey on breast cancer survivors. <i>Maturitas</i> , 2003, 45, 29-38.	2.4	225
2	Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 67-76.	2.5	225
3	Correlations between diffusion-weighted imaging and breast cancer biomarkers. <i>European Radiology</i> , 2012, 22, 1519-1528.	4.5	206
4	Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. <i>International Journal of Cancer</i> , 2003, 103, 466-474.	5.1	182
5	miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. <i>FASEB Journal</i> , 2013, 27, 1223-1235.	0.5	134
6	Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. <i>Gynecological Endocrinology</i> , 2010, 26, 404-412.	1.7	121
7	Effects of Surgical and Adjuvant Therapies for Breast Cancer on Sexuality, Cognitive Functions, and Body Weight. <i>Journal of Sexual Medicine</i> , 2010, 7, 1891-1900.	0.6	96
8	Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 171-178.	2.5	92
9	Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. <i>Clinical Chemistry</i> , 2002, 48, 1241-1250.	3.2	82
10	Vaginal oestrogen therapy after breast cancer: Is it safe?. <i>European Journal of Cancer</i> , 2005, 41, 2673-2681.	2.8	79
11	Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. <i>International Journal of Cancer</i> , 2008, 123, 1327-1338.	5.1	79
12	Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 1418-1425.	3.7	79
13	Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: The Prevalent Mutation G985 (K304E) Is Subject to a Strong Founder Effect from Northwestern Europe. <i>Human Heredity</i> , 1993, 43, 342-350.	0.8	75
14	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	1.6	69
15	Comparison of two models for the prediction of nonsentinel node metastases in breast cancer. <i>American Journal of Surgery</i> , 2007, 193, 686-692.	1.8	66
16	MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy. <i>European Journal of Cancer</i> , 2015, 51, 1882-1889.	2.8	63
17	Neoadjuvant or adjuvant chemotherapy in early breast cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1071-1082.	1.8	62
18	Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. <i>British Journal of Cancer</i> , 2002, 86, 1457-1464.	6.4	58

#	ARTICLE	IF	CITATIONS
19	Extensive Nodal Disease May Impair Axillary Reverse Mapping in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5547-5551.	1.6	57
20	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. <i>European Radiology</i> , 2007, 17, 1490-1497.	4.5	56
21	Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. <i>European Journal of Cancer</i> , 2012, 48, 2311-2318.	2.8	55
22	Prostate-specific antigen in serum of women with breast cancer. <i>British Journal of Cancer</i> , 1995, 72, 728-731.	6.4	54
23	Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. <i>Maturitas</i> , 2005, 52, 78-85.	2.4	54
24	Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. <i>British Journal of Cancer</i> , 1997, 76, 1087-1094.	6.4	50
25	Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. <i>Climacteric</i> , 2009, 12, 310-318.	2.4	49
26	The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 149-158.	2.5	46
27	The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. <i>British Journal of Cancer</i> , 1999, 79, 311-315.	6.4	43
28	Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1163-1184.	2.6	43
29	Axillary Reverse Mapping in Breast Cancer: Can we Spare what we Find?. <i>Annals of Surgical Oncology</i> , 2008, 15, 390-391.	1.5	43
30	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. <i>Gynecologic Oncology</i> , 2015, 138, 627-633.	1.4	43
31	Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. <i>British Journal of Cancer</i> , 1996, 73, 386-390.	6.4	42
32	The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. <i>British Journal of Cancer</i> , 2002, 87, 1294-1300.	6.4	42
33	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	10.7	41
34	Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. <i>British Journal of Cancer</i> , 2002, 87, 1287-1293.	6.4	40
35	Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test. <i>European Journal of Pediatrics</i> , 1993, 152, 655-661.	2.7	38
36	Indications for breast magnetic resonance imaging. Consensus document "Attualità in senologia", Florence 2007. <i>Radiologia Medica</i> , 2008, 113, 1085-1095.	7.7	38

#	ARTICLE	IF	CITATIONS
37	Nipple-areola complex sparing mastectomy with periareolar pexy for breast cancer patients with moderately ptotic breasts. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2012, 65, 296-303.	1.0	33
38	Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. <i>Clinical Chemistry</i> , 2002, 48, 1241-50.	3.2	33
39	Hormone replacement therapy in cancer survivors. <i>Maturitas</i> , 2004, 48, 333-346.	2.4	31
40	Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. <i>Annals of Oncology</i> , 2006, 17, 1631-1636.	1.2	30
41	Mirtazapine for the Treatment of Hot Flashes in Breast Cancer Survivors: A Prospective Pilot Trial. <i>Breast Journal</i> , 2007, 13, 490-495.	1.0	28
42	Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. <i>Ecancermedalscience</i> , 2016, 10, 639.	1.1	28
43	Hyperphenylalaninemia and pterin metabolism in serum and erythrocytes. <i>Clinica Chimica Acta</i> , 1993, 216, 63-71.	1.1	25
44	Aromatase inhibitors for breast cancer: different structures, same effects?. <i>Endocrine-Related Cancer</i> , 2008, 15, 27-36.	3.1	25
45	Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers. <i>Clinical Breast Cancer</i> , 2018, 18, e1361-e1366.	2.4	25
46	Antihormones in Prevention and Treatment of Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 143-158.	3.8	24
47	Role of re-excision for positive and close resection margins in patients treated with breast-conserving surgery. <i>Breast</i> , 2014, 23, 870-875.	2.2	24
48	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two-centers experience. <i>Journal of Ovarian Research</i> , 2018, 11, 42.	3.0	21
49	Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3755-3761.	1.5	20
50	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 775-784.	2.5	19
51	Variation of Breast Vascular Maps on Dynamic Contrast-Enhanced MRI After Primary Chemotherapy of Locally Advanced Breast Cancer. <i>American Journal of Roentgenology</i> , 2011, 196, 1214-1218.	2.2	19
52	Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 167-174.	2.5	19
53	Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. <i>Journal of Clinical Laboratory Analysis</i> , 1999, 13, 75-81.	2.1	18
54	Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 85-95.	2.5	18

#	ARTICLE	IF	CITATIONS
55	Management of risk of breast carcinoma in postmenopausal women.. Endocrine-Related Cancer, 2004, 11, 69-83.	3.1	17
56	Does our better understanding of breast cancer also improve the way we treat it?. Gland Surgery, 2013, 2, 1-3.	1.1	16
57	Personal use of HRT by postmenopausal women doctors and doctors' wives in the north of Italy. Gynecological Endocrinology, 2004, 18, 165-174.	1.7	15
58	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget, 2016, 7, 26181-26191.	1.8	15
59	Personal use of hormone therapy by postmenopausal women doctors and male doctors's wives in Italy after the publication of WHI trial. Maturitas, 2006, 54, 181-192.	2.4	13
60	Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes. Maturitas, 2007, 57, 50-55.	2.4	13
61	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Npj Breast Cancer, 2021, 7, 16.	5.2	13
62	Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. Radiologia Medica, 2003, 106, 51-8.	7.7	13
63	Catalytic Activity of Tetrahydrobiopterin in Dihydropteridine Reductase Deficiency and Indications for Treatment. Pediatric Research, 1993, 33, 125-128.	2.3	12
64	Modification of serum IGF-I, IGFBNs and SHBG levels by different HRT regimens. Maturitas, 2003, 45, 283-291.	2.4	11
65	Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. , 1998, 79, 147-152.		10
66	Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. British Journal of Cancer, 2014, 110, 1133-1138.	6.4	10
67	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. ESMO Open, 2020, 5, e000937.	4.5	10
68	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. ESMO Open, 2021, 6, 100300.	4.5	9
69	Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer. Cancer Treatment Reviews, 2016, 48, 1-7.	7.7	8
70	MRI to predict nipple-areola complex (NAC) involvement: An automatic method to compute the 3D distance between the NAC and tumor. Journal of Surgical Oncology, 2017, 116, 1069-1078.	1.7	8
71	Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine. Journal of the National Cancer Institute, 2004, 96, 883-884.	6.3	7
72	Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal. Breast, 2020, 53, 181-188.	2.2	7

#	ARTICLE	IF	CITATIONS
73	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020, 9, 442.	4.1	7
74	Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. <i>Clinical Biochemistry</i> , 1999, 32, 39-44.	1.9	6
75	HRT, breast and endometrial cancers: strategies and intervention options. <i>Maturitas</i> , 1999, 32, 131-139.	2.4	6
76	Loco-regional therapy and breast cancer survival: Searching for a link. <i>Breast</i> , 2013, 22, 510-514.	2.2	6
77	Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. <i>Cancers</i> , 2020, 12, 2239.	3.7	6
78	BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103128.	4.4	6
79	Monitoring Treatment in Tetrahydrobiopterin Deficiency. <i>Pteridines</i> , 1991, 3, 13-15.	0.5	6
80	Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer. <i>Journal of Chemotherapy</i> , 2006, 18, 90-97.	1.5	5
81	Accelerated partial breast irradiation using 3D conformal radiotherapy: Toxicity and cosmetic outcome. <i>Breast</i> , 2013, 22, 1136-1141.	2.2	5
82	Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome. <i>Journal of Clinical Medicine</i> , 2019, 8, 313.	2.4	5
83	The Value of Repeated Breast Surgery as a Quality Indicator in Breast Cancer Care. <i>Annals of Surgical Oncology</i> , 2021, 28, 340-352.	1.5	5
84	RFLPs of the phenylalanine hydroxylase gene in the Italian population. <i>Journal of Inherited Metabolic Disease</i> , 1989, 12, 162-165.	3.6	4
85	Oral Contraceptive Use and Breast Cancer Risk in Areas with Different Incidence.. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 564-569.	3.8	4
86	Pathological classification of ductal carcinoma in situ of the breast correlates with surgical treatment and may be predicted by mammography. <i>Breast</i> , 2007, 16, 495-502.	2.2	4
87	The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study. <i>Cancers</i> , 2021, 13, 5836.	3.7	4
88	Decreasing arm morbidity by refining axillary surgery in breast cancer. <i>European Journal of Surgical Oncology</i> , 2009, 35, 335-338.	1.0	3
89	Term breech trial. <i>Lancet, The</i> , 2001, 357, 226-227.	13.7	2
90	Beyond randomized controlled trials. <i>Cancer</i> , 2002, 94, 579-580.	4.1	2

#	ARTICLE	IF	CITATIONS
91	Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1&2 mutation carriers. <i>Maturitas</i> , 2008, 60, 71-77.	2.4	2
92	Breast Cancer Prevention: Can Women's Expectations Be Met?. <i>Oncologist</i> , 2016, 21, 2-3.	3.7	2
93	Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence. <i>Breast</i> , 2018, 41, 8-13.	2.2	2
94	Is breast conserving therapy better than mastectomy? Surgeons must speak out. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1551-1553.	1.0	2
95	Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Status: An Independent Influence on the Efficacy of Endocrine Therapy in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2006, 24, 1481-1482.	1.6	1
96	Patients With Breast Cancer Are Unlikely to Benefit From Prophylactic Irradiation of the Contralateral Breast. <i>Journal of Clinical Oncology</i> , 2008, 26, 1014-1015.	1.6	1
97	A retrospective analysis on 197 cases of breast cancer local recurrence: Biology, treatment, and prognosis. <i>Breast Journal</i> , 2020, 26, 1096-1098.	1.0	1
98	Prenatal Diagnosis of Dihydropteridine Reductase Deficiency in a Twin Pregnancy. <i>Pteridines</i> , 1991, 3, 19-21.	0.5	1
99	The Academic Division of Breast and Gynaecological Oncology of the Institute for Cancer Research and Treatment (IRCC) of Candiolo, Turin, Italy. <i>Breast Care</i> , 2008, 3, 287-288.	1.4	0
100	Do all BRCA1/2 carriers with breast cancer benefit from bilateral mastectomy?. <i>Annals of Breast Surgery</i> , 2019, 3, 23-23.	0.8	0
101	ASO Author Reflections: The Difficult Assessment of the Hard-Won Progress of Breast Cancer Care. <i>Annals of Surgical Oncology</i> , 2020, 27, 777-778.	1.5	0
102	Does immediate reconstruction increase postmastectomy surgical site infection?. <i>Gland Surgery</i> , 2012, 1, 167-8.	1.1	0